FDA moves toward easing restrictions on certain peptides BioPharma Dive Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link Peptides, Drugs And Supplements: Science, Risks, And Alternatives Los Angeles Times Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with